Dongwha Pharm.Co.,Ltd

KOSE:A000020 Stock Report

Market Cap: ₩182.9b

Dongwha Pharm.Co.Ltd Balance Sheet Health

Financial Health criteria checks 4/6

Dongwha Pharm.Co.Ltd has a total shareholder equity of ₩405.9B and total debt of ₩57.8B, which brings its debt-to-equity ratio to 14.2%. Its total assets and total liabilities are ₩587.1B and ₩181.2B respectively. Dongwha Pharm.Co.Ltd's EBIT is ₩8.9B making its interest coverage ratio -5.7. It has cash and short-term investments of ₩40.1B.

Key information

14.2%

Debt to equity ratio

₩57.82b

Debt

Interest coverage ratio-5.7x
Cash₩40.09b
Equity₩405.92b
Total liabilities₩181.18b
Total assets₩587.11b

Recent financial health updates

Recent updates

Dongwha Pharm.Co.Ltd's (KRX:000020) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Nov 20
Dongwha Pharm.Co.Ltd's (KRX:000020) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Dongwha Pharm.Co.Ltd's (KRX:000020) Promising Earnings May Rest On Soft Foundations

Mar 26
Dongwha Pharm.Co.Ltd's (KRX:000020) Promising Earnings May Rest On Soft Foundations

Is Dongwha Pharm.Co.,Ltd (KRX:000020) A Smart Pick For Income Investors?

Apr 28
Is Dongwha Pharm.Co.,Ltd (KRX:000020) A Smart Pick For Income Investors?

These 4 Measures Indicate That Dongwha Pharm.Co.Ltd (KRX:000020) Is Using Debt Safely

Mar 11
These 4 Measures Indicate That Dongwha Pharm.Co.Ltd (KRX:000020) Is Using Debt Safely

Dongwha Pharm.Co.,Ltd (KRX:000020) Has A ROE Of 8.6%

Feb 22
Dongwha Pharm.Co.,Ltd (KRX:000020) Has A ROE Of 8.6%

Is Dongwha Pharm.Co.Ltd's (KRX:000020) Share Price Gain Of 102% Well Earned?

Feb 07
Is Dongwha Pharm.Co.Ltd's (KRX:000020) Share Price Gain Of 102% Well Earned?

Should Dongwha Pharm.Co.,Ltd (KRX:000020) Be Part Of Your Dividend Portfolio?

Jan 23
Should Dongwha Pharm.Co.,Ltd (KRX:000020) Be Part Of Your Dividend Portfolio?

Is Dongwha Pharm.Co.,Ltd (KRX:000020) Popular Amongst Insiders?

Jan 08
Is Dongwha Pharm.Co.,Ltd (KRX:000020) Popular Amongst Insiders?

Dongwha Pharm.Co.,Ltd (KRX:000020) Pays A ₩120 Dividend In Just Four Days

Dec 24
Dongwha Pharm.Co.,Ltd (KRX:000020) Pays A ₩120 Dividend In Just Four Days

We're Not Counting On Dongwha Pharm.Co.Ltd (KRX:000020) To Sustain Its Statutory Profitability

Dec 19
We're Not Counting On Dongwha Pharm.Co.Ltd (KRX:000020) To Sustain Its Statutory Profitability

Is Dongwha Pharm.Co.Ltd (KRX:000020) Using Too Much Debt?

Dec 04
Is Dongwha Pharm.Co.Ltd (KRX:000020) Using Too Much Debt?

Can Dongwha Pharm.Co.,Ltd (KRX:000020) Improve Its Returns?

Nov 19
Can Dongwha Pharm.Co.,Ltd (KRX:000020) Improve Its Returns?

Financial Position Analysis

Short Term Liabilities: A000020's short term assets (₩218.2B) exceed its short term liabilities (₩108.2B).

Long Term Liabilities: A000020's short term assets (₩218.2B) exceed its long term liabilities (₩73.0B).


Debt to Equity History and Analysis

Debt Level: A000020's net debt to equity ratio (4.4%) is considered satisfactory.

Reducing Debt: A000020's debt to equity ratio has increased from 0% to 14.2% over the past 5 years.

Debt Coverage: A000020's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: A000020 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies